Subscribe   RSS Contact Us

Pitts Calls Higher Drug Approval Rate a Sign of Regulatory Progress

Aug. 24, 2015 – Although some may call the FDA to task for approving more new drugs than they have ... read more

CHC and CCC Launching Regulatory Compliance University for Agencies, Publishers

Aug. 19, 2015 – The Coalition for Healthcare Communication (CHC) is partnering with the Center for Communication Compliance (CCC) to ... read more

Kamp on Presidential Politics: They Matter to Medical Marketers

Aug. 17, 2015 – In an Aug. 11 column posted on the PharmaLive website, Coalition for Healthcare Communication Executive Director ... read more

Amarin Federal Court Decision: FDA Off-Label Marketing Rules Violate the First Amendment By John Kamp

Aug. 10, 2015 – Late last week the U.S. District Court for the Southern District of New York granted Amarin ... read more

FDA Will Study How Market Claims, Efficacy Info Affect Consumers in DTC Drug Print Ads

July 29, 2015 – The FDA’s Office of Prescription Drug Promotion (OPDP) recently announced that it plans to conduct a ... read more

Congressional Briefing: Medical Information Communication Is Important Patient Issue

July 28, 2015 – Physicians and their patients need access to truthful and non-misleading data about available treatments, including off-label ... read more

CME Update: CMS Revises Guidance and Industry Ups Spending

July 20, 2015 – Two recent developments in the continuing medical education (CME) arena – a revision to CME guidance ... read more

Kamp: 21st Century Cures Act and Amarin Case Developments Are Signs of Progress

July 13, 2015 –Two events last week – the House approval of the 21st Century Cures legislation and arguments in ... read more

House Approves 21st Century Cures Act, Bill Now Heads to the Senate

July 10, 2015 — The House of Representatives today passed H.R. 6, also known as the 21st Century Cures Act, ... read more

21st Century Cures Legislation Garners House Majority Support

July 1, 2015 – The 21st Century Cures Act, which was unanimously approved by the House Energy and Commerce Committee ... read more

Google SEM Changes Affect Drug Black Box Reminder-like, Redirecting Ads

June 29, 2015 – Two changes to search engine marketing (SEM) recently announced by Google could soon alter how pharmaceutical ... read more

Physicians Say CHC-backed H.R. 293 Would Remedy “Burdensome” Sunshine Act Reporting

June 15, 2015 – More than 100 physician organizations have written to Rep. Michael Burgess (R-TX) to express their strong ... read more

Author of “Pharmaphobia” Says Conflict-of-interest Regulations Are Slowing Medical Progress

June 8, 2015 – In his new book, “Pharmaphobia: How the Conflict of Interest Myth Undermines American Medical Innovation,” Tom ... read more

Revised Guidance on Use of Brief Summary in Print DTC Ads: Full PI Is Not Needed or “Recommended”

Feb. 9, 2015 – In a revised draft guidance document released Feb. 6, the FDA is updating a 2004 version ... read more

Previous Next

Coalition and Med Ad News Present Healthcare Podcasts

You can visit to download podcasts on healthcare issues by John Kamp, the Coalition”s Executive Director.

persuasive essay writing

The 1st is on the defeated but still looming ad tax bill. The 2nd is an overview and analysis of the “New FDA.”

Med Ad News plans to present 3 more podcasts in this series.bayer cipro prostatitis

Study Finds CME Funding Doesn’t Create Bias

A new study by 4 researchers from the Cleveland Clinic showed that industry support of continuing medical education created no bias among participants.

The study acknowledges the controversy surrounding CME funding, then explains how it tested for bias among its participants. It is important to note that no previously published studies have addressed this perceived bias.

Peter Pitts Tells Why FDA DDMAC Letter to Bauman Isn’t a First Amendment Issue

From :

Much brouhaha about the DDMAC letter sent to Dr. Leslie Bauman about her enthusiastic comments about a yet-to-be-approved anti wrinkle injectable.

At first blush, this seems like regulatory creep and cause for First Amendment agita. But it isn”t. This is not a case of the FDA trying to stifle unregulated speech by an individual without “interest.” Dr. Bauman is a clinical And if you need to relax and unwind a little, what can be better than playing a fun game, which will not set your bank account short? Here on Slotozilla, you can play free slot machines any time of day, with no breaks and no curfews. investigator for the product she”s been touting. That”s “interest” whether the trial sponsor paid her to do so or not. (In this instance, there was no “pay for play.”) In any case, it”s an unambiguous regulatory no-no.

descriptive essay

Your comments are welcome here.internet viagra pharmacy

MM&M Profiles Tom Sullivan, a Forceful Defender of CME

The February issue of MM&M magazine spotlights Policymed.com blogger Tom Sullivan.

personal essay definition

Read the articleviagra, candadian drugs

Results 1-4 of 4